Pharma · Private company
Janssen Research & Development, LLC
Track this companyFree. Adds Janssen Research & Development, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs53From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline53
- Abiraterone acetate (AA)Phase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- AmivantamabPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- BortezomibPhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- CarfilzomibPhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- ChlorambucilPhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- DeucravacitinibPhase 3 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- ErdafitinibPhase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- EtanerceptPhase 3 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)Phase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- GuselkumabPhase 3 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- GuselkumabPhase 3 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- GuselkumabPhase 3 · Arthritis, PsoriaticClinicalTrials.gov · fetched Nov 12, 2026
- Guselkumab Dose 1Phase 3 · Colitis, UlcerativeClinicalTrials.gov · fetched Nov 12, 2026
- Guselkumab Dose 2Phase 3 · Colitis, UlcerativeClinicalTrials.gov · fetched Nov 12, 2026
- Guselkumab Dose 3Phase 3 · Colitis, UlcerativeClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- Ibrutinib (as Subsequent Therapy)Phase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- JNJ-77242113Phase 3 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- LazertinibPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- NipocalimabPhase 3 · Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Nipocalimab SC-LIVPhase 3 · Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Niraparib+ Abiraterone acetate fixed dose combination (FDC)Phase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- OsimertinibPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- PomalidomidePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TeclistamabPhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- VinfluninePhase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- BleximenibPhase 2 · Acute LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- GolimumabPhase 2 · Crohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GolimumabPhase 2 · Colitis, UlcerativeClinicalTrials.gov · fetched Nov 12, 2026
- GuselkumabPhase 2 · Crohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GuselkumabPhase 2 · Colitis, UlcerativeClinicalTrials.gov · fetched Nov 12, 2026
- JNJ-78934804Phase 2 · Colitis, UlcerativeClinicalTrials.gov · fetched Nov 12, 2026
- JNJ-78934804Phase 2 · Crohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AmivantamabPhase 1 · Non-Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · Non-Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- JNJ-87890387Phase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- JNJ-88549968Phase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- LazertinibPhase 1 · Non-Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- MomelotinibPhase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 1 · Non-Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- RuxolitinibPhase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TalquetamabPhase 1 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- Teclistamab (IV)Phase 1 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- Teclistamab(SC)Phase 1 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)PHASE1_PHASE2 · RECRUITING · started Oct 12, 2026ClinicalTrials.gov NCT07871435 · fetched Nov 12, 2026
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 9, 2024ClinicalTrials.gov NCT06220604 · fetched Nov 12, 2026
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 17, 2024ClinicalTrials.gov NCT06143878 · fetched Nov 12, 2026
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsPHASE1 · RECRUITING · started Dec 20, 2023ClinicalTrials.gov NCT06150157 · fetched Nov 12, 2026
- A Study of JNJ-87890387 for Advanced Solid TumorsPHASE1 · RECRUITING · started Dec 14, 2023ClinicalTrials.gov NCT06178614 · fetched Nov 12, 2026
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque PsoriasisPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 12, 2023ClinicalTrials.gov NCT06095115 · fetched Nov 12, 2026
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 29, 2023ClinicalTrials.gov NCT05572515 · fetched Nov 12, 2026
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 19, 2022ClinicalTrials.gov NCT05242484 · fetched Nov 12, 2026
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative ColitisPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 13, 2022ClinicalTrials.gov NCT05528510 · fetched Nov 12, 2026
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseasePHASE2 · ACTIVE_NOT_RECRUITING · started Jul 22, 2022ClinicalTrials.gov NCT05242471 · fetched Nov 12, 2026
- A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisPHASE2_PHASE3 · RECRUITING · started Jul 20, 2022ClinicalTrials.gov NCT05265273 · fetched Nov 12, 2026
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailurePHASE3 · ACTIVE_NOT_RECRUITING · started Nov 17, 2021ClinicalTrials.gov NCT04988295 · fetched Nov 12, 2026
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisPHASE3 · RECRUITING · started Jul 15, 2021ClinicalTrials.gov NCT04951622 · fetched Nov 12, 2026
- A Study of Guselkumab in Participants With Active Psoriatic ArthritisPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 17, 2021ClinicalTrials.gov NCT04882098 · fetched Nov 12, 2026
- A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)PHASE1_PHASE2 · RECRUITING · started May 19, 2021ClinicalTrials.gov NCT04811560 · fetched Nov 12, 2026
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 30, 2020ClinicalTrials.gov NCT04487080 · fetched Nov 12, 2026
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 23, 2020ClinicalTrials.gov NCT04497844 · fetched Nov 12, 2026
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 26, 2019ClinicalTrials.gov NCT04033445 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric ParticipantsPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 11, 2018ClinicalTrials.gov NCT03451851 · fetched Nov 12, 2026
- A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 17, 2018ClinicalTrials.gov NCT03462719 · fetched Nov 12, 2026
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 23, 2018ClinicalTrials.gov NCT03390504 · fetched Nov 12, 2026
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 16, 2017ClinicalTrials.gov NCT03399799 · fetched Nov 12, 2026
- Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple MyelomaPHASE1 · ACTIVE_NOT_RECRUITING · started May 16, 2017ClinicalTrials.gov NCT03145181 · fetched Nov 12, 2026
- Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerPHASE1 · ACTIVE_NOT_RECRUITING · started May 24, 2016ClinicalTrials.gov NCT02609776 · fetched Nov 12, 2026
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 9, 2013ClinicalTrials.gov NCT01804686 · fetched Nov 12, 2026